Therapeutics clinic

New horizons in migraine therapy: CGRP monoclonal antibodies

Therapeutics clinic

New horizons in migraine therapy: CGRP monoclonal antibodies

JASON C. RAY, ELSPETH J. HUTTON, Shuli Cheng, LIN ZHANG, RICHARD J. STARK

Figures

© fred goldstein/ stock.adobe.com model used for illustratrive purposes only
© fred goldstein/ stock.adobe.com model used for illustratrive purposes only

Abstract

Migraine is one of the most common and disabling diseases worldwide. However, few disease-specific treatments exist. Calcitonin-gene related peptide (CGRP) monoclonal antibodies are a new class of medication for migraine that represent a welcome addition to our armamentarium for migraine.

Article Extract

Migraine is the most common neurological disease worldwide, affecting over one billion people. Worldwide, it is the second leading cause of age-adjusted disability life years (DALYs).1 In Australasia, it is the leading neurological cause of DALYs, ahead of stroke (which is second), epilepsy (sixth) and multiple sclerosis (10th).1 The health economic burden of migraine is significant and has been estimated at $35.7 billion, with $14.3 billion in direct health costs throughout Australia in 2018.1,2